Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib versus adalimumab in relapsing refractory Takayasu's arteritis
ChiCTR2500102833Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of deucravacitinib and adalimumab in Takayasu arteritis (TAK) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Overall response rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
deucravacitinibadalimumab
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on ChiCTR2500102833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102833.